A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

NCT02720510 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped A study was terminated due to low enrollment.

Conditions

Multiple Myeloma

Interventions

DRUG: Revlimid
DRUG: Velcade
DRUG: dexamethasone
DRUG: Farydak

Sponsor

Novartis Pharmaceuticals